Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
EV/EBIT
31.32 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its Earnings Before Interest and Taxes (EBIT). As of today, Valeant Pharmaceuticals International Inc's enterprise value is $63,603 Mil. Valeant Pharmaceuticals International Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was $2,031 Mil. Therefore, Valeant Pharmaceuticals International Inc's EV/EBIT ratio for today is 31.32.

VRX' s EV/EBIT Range Over the Past 10 Years
Min: -1086.7   Max: 414.9
Current: 51.68

-1086.7
414.9

During the past 13 years, the highest EV/EBIT Ratio of Valeant Pharmaceuticals International Inc was 414.90. The lowest was -1086.70. And the median was 17.60.

VRX's EV/EBIT is ranked lower than
87% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.36 vs. VRX: 51.68 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). Valeant Pharmaceuticals International Inc's enterprise value for the quarter that ended in Sep. 2015 was $90,786 Mil. Valeant Pharmaceuticals International Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was $2,031 Mil. Valeant Pharmaceuticals International Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2015 was 2.24%.


Definition

Valeant Pharmaceuticals International Inc's EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Earnings Before Interest and Taxes (EBIT) (TTM)
=63602.871/2030.7
=31.32

Valeant Pharmaceuticals International Inc's current Enterprise Value is $63,603 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was 815 (Dec. 2014 ) + 453.2 (Mar. 2015 ) + 348 (Jun. 2015 ) + 414.5 (Sep. 2015 ) = $2,031 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

Valeant Pharmaceuticals International Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2015 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Sep. 2015 )=EBIT (TTM)/Enterprise Value (Q: Sep. 2015 )
=2030.7/90786.0942
=2.24 %

Valeant Pharmaceuticals International Inc's Enterprise Value for the quarter that ended in Sep. 2015 was $90,786 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was 815 (Dec. 2014 ) + 453.2 (Mar. 2015 ) + 348 (Jun. 2015 ) + 414.5 (Sep. 2015 ) = $2,031 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Enterprise Value, Earnings Yield (Joel Greenblatt), Earnings Before Interest and Taxes (EBIT)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
ev2ebit 22.35-8.446.2515.3015.81-160.7872.29139.93-87.6553.25

Valeant Pharmaceuticals International Inc Quarterly Data

Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15
ev2ebit 134.17-78.47-87.65-133.86-252.6848.2253.2569.9077.6577.94
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK